XXXX induces apoptosis and @entity137 of @entity1778 cells alone and in combination with purine nucleoside analogs in @entity1072 .

@entity1 @entity8778 @entity137 @entity522 @entity17262 @entity11441 @entity5 @entity1872 @entity1072 @entity8187 @entity8186 @entity8742 @entity3118 @entity1778
UNASSIGNED: Recently, great progress has been achieved in the treatment of @entity1072 ( @entity1072 ). However, some @entity1 , particularly older @entity1 with comorbidities or with relapsed/ @entity1778 , still have limited therapeutic options. There is an urgent need to discover less toxic and more effective drugs for @entity1072 @entity1 . Applying new modalities or substances that are widely used for the treatment of other diseases has been reported to improve results in @entity1072 treatment. This study aimed to assess the non-chemotherapeutic drug @entity1872 for its potential to destroy @entity1778 cells. Leukemic cells, obtained from the peripheral blood and bone marrow of 23 @entity1072 @entity1 , were cultured in the presence of @entity1872 and its combination with the purine @entity8742 analogs @entity3118 and @entity8778 and @entity11441 . After 24  h of incubation, the rate of apoptosis indicated by active @entity522 expression, and @entity137 indicated by forward light scatter and light scatter analysis, was assessed by flow cytometry. We also measured expression of apoptosis-regulating proteins of BCL family and active @entity8187 and active @entity8186 expressions in @entity1778 cells. @entity1872 had a caspase-dependent pro-apoptotic and cytotoxic effect on @entity1778 cells in a @entity5 -specific manner. The mechanisms of its action appear to be complex and should be precisely established; however, induction of apoptosis involving both mitochondrial and receptor cascades appears to be most probable. @entity1872 showed a synergic effect with @entity8778 , an additive effect with @entity3118 , and an infra-additive effect with @entity11441 . The rate of @entity1872 -induced apoptosis and @entity137 did not differ between @entity1 with better and worse prognostic markers. Our results indicate that @entity1872 may be a potential therapeutic agent for @entity1072 @entity1 alone and in combination with @entity17262 analogs.
